These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 101843)

  • 21. CCNU, melphalan, methotrexate, and prednisone (CAMP) versus cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in the treatment of advanced breast cancer in postmenopausal women.
    Salimtschik M; Snel S; Havsteen H; Dombernowsky P; Mouridsen HT
    Cancer Treat Rep; 1980; 64(4-5):635-7. PubMed ID: 7000346
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Pasmantier MW; Coleman M; Silver RT; Ballard WP
    Cancer Treat Rep; 1985 Jun; 69(6):689-93. PubMed ID: 3926310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
    Greco FA; Julian CG; Richardson RL; Burnett L; Hande KR; Oldham RK
    Obstet Gynecol; 1981 Aug; 58(2):199-205. PubMed ID: 6789265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled prospective trial of combination chemotherapy with cyclophosphamide, adriamycin, and 5-fluorouracil for the treatment of advanced ovarian cancer: a preliminary report.
    Bruckner HW; Pagano M; Falkson G; Creech R; Arseneau JC; Horton J; Brodovsky H; Davis TE; Slayton RW; Greenspan E
    Cancer Treat Rep; 1979 Feb; 63(2):297-9. PubMed ID: 376136
    [No Abstract]   [Full Text] [Related]  

  • 26. Primary treatment of advanced ovarian adenocarcinoma, stages III and IV.
    Piver S; Barlow JJ; Chung WS; Lee FT; Vongtama V
    Natl Cancer Inst Monogr; 1975 Oct; 42():177-82. PubMed ID: 825780
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preliminary report of a clinical trial of the treatment of patients with advanced stage III and IV ovarian cancer with melphalan, 5-fluorouracil, and methotrexate in combination and sequentially: a study of the Clinical Trials Group of the National Cancer Institute of Canada.
    Klaassen DJ; Boyes DA; Gerulath A; Levitt M; Miller AB; Pearson JG
    Cancer Treat Rep; 1979 Feb; 63(2):289-95. PubMed ID: 376135
    [No Abstract]   [Full Text] [Related]  

  • 28. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
    Pater JL; Carmichael JA; Krepart GV; Fraser RC; Roy M; Kirk ME; Levitt M; Brown LB; Wilson KS; Shelley WE
    Cancer Treat Rep; 1987 Mar; 71(3):277-81. PubMed ID: 3102056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single agent vs combination chemotherapy in the treatment of ovarian cancer.
    Barlow JJ; Piver MS
    Obstet Gynecol; 1977 May; 49(5):609-11. PubMed ID: 850579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.
    Omura GA; Morrow CP; Blessing JA; Miller A; Buchsbaum HJ; Homesley HD; Leone L
    Cancer; 1983 Mar; 51(5):783-9. PubMed ID: 6401594
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.
    Edwards CL; Herson J; Gershenson DM; Copeland LJ; Wharton JT
    Gynecol Oncol; 1983 Apr; 15(2):261-77. PubMed ID: 6403413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary.
    de Palo GM; de Lena M; Di Re F; Luciani L; Valagussa P; Bonadonna G
    Surg Gynecol Obstet; 1975 Dec; 141(6):899-902. PubMed ID: 1103333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of advanced ovarian cancer].
    de Gramont A; Krulik M; Pigne A; Brissaud P; Sirinelli A; Hubert D; Zylberait D; Debray J
    Sem Hop; 1984 Mar; 60(14):957-60. PubMed ID: 6326283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
    Vogl SE; Pagano M; Davis TE; Einhorn N; Tunca JC; Kaplan BH; Arseneau JC
    Cancer Treat Rep; 1982 Jun; 66(6):1285-90. PubMed ID: 6282454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
    Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
    Neth J Med; 1979; 22(2):38-44. PubMed ID: 107464
    [No Abstract]   [Full Text] [Related]  

  • 37. Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
    Carmo-Pereira J; Costa FO; Henriques E; Ricardo JA
    Cancer; 1981 Nov; 48(9):1947-51. PubMed ID: 6271386
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial.
    Alberts DS; Hilgers RD; Moon TE; Martimbeau PW; Rivkin S
    Cancer Treat Rep; 1979 Feb; 63(2):301-5. PubMed ID: 109200
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
    de Gramont A; Drolet Y; Louvet C; Dray C; Krulik M; Pigné A; Lavoie A; Painchaud M; Blouin R; Tessier C
    J Gynecol Obstet Biol Reprod (Paris); 1986; 15(1):105-9. PubMed ID: 3084619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.